The Question for Retirees Owning ARKK or KOMP Is How Much One Bad Stock Should Hurt
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
ARK Innovation ETF (CBOE:ARKK) and State Street SPDR S&P Kensho New Economies Composite ETF (NYSEARCA:KOMP) both sell investors a stake in the future, but they hold it in opposite ways. ARKK packs its money into a short list of high-conviction names, while KOMP spreads the same theme across a long list of small positions. ARKK recently traded at $68.93 and KOMP at $56.88. For anyone at or near retirement, the deciding factor is how much single-stock risk an innovation fund should carry.
Two Ways to Buy Innovation
ARK Invest describes ARKK as an actively managed ETF seeking long-term growth of capital. That means a research team picks every stock and sizes each position by conviction. KOMP is an index fund that seeks to track the S&P Kensho New Economies Composite Index. That index screens for companies tied to sectors such as robotics, genomics, clean energy, and space. Its rules decide what gets in, and they keep each position small.
It’s All About Concentration
Concentration describes how much of a fund rides on its biggest holdings. ARKK also owns private OpenAI shares worth 3.10%[1] of net assets (holdings minus liabilities), a stake that trades on no exchange. Compare the top of each portfolio:
| ARKK (as of Jul 31, 2026) | KOMP (as of Nov 17, 2026) |
|---|---|
| Tesla 9.74%[1] | PTC 1.57% |
| Tempus AI 4.89%[1] | Unity Software 1.40% |
| SpaceX 4.87%[1] | Twist Bioscience 1.37% |
| CRISPR Therapeutics 4.73%[1] | Bruker 1.24% |
| Shopify 4.36%[1] | Elbit Systems 1.10% |
KOMP’s single largest holding is smaller than ARKK’s sixth-largest, Coinbase, at 4.17%[1]. A bad quarter at Tesla visibly dents ARKK. Similar news would barely register in KOMP.
Where They Overlap
| Holding | ARKK (Jul 31, 2026) | KOMP (as of Nov 17, 2026) |
|---|---|---|
| Tesla | 9.74%[1] | 0.86% |
| Twist Bioscience | 3.31%[1] | 1.37% |
| Meta Platforms | 1.56%[1] | 0.80% |
| CRISPR Therapeutics | 4.73%[1] | 0.09% |
Same companies, very different stakes. Owning both funds adds little diversification on these names.
Performance: Concentration’s Trade-Off
| Period | ARKK | KOMP |
|---|---|---|
| One month | −18.95% | −9.61% |
| Year to date | −12.1% | −4.34% |
| One year | −9.11% | −1.26% |
| Five years | −39.46% | −6.82% |
| Longest available | 250.22% (ten years) | 110.97% (since Oct 23, 2018) |
The longest-period figures cover different windows and cannot be compared directly. ARKK’s ten-year gain shows what concentration pays when its picks take off. The five-year line shows the other side: ARKK lost far more of its value, and it fell harder in every shorter period too.
What It Costs
The expense ratio is the annual fee, taken as a share of assets. ARK lists ARKK’s at 0.75%, while State Street lists KOMP’s at 0.2%. That gap comes out of returns every year, so it grows with each year a long-term holder stays in. Both funds have ample scale: KOMP manages $2.35 billion per State Street, and ARKK reported $5.56 billion[1] in net assets.
Which One Better Fits a Retirement Portfolio
KOMP’s structure lines up more closely with the priorities many retirement-minded investors describe. It holds the innovation theme at a lower cost, and no single stock can sink it. ARKK’s profile resembles a satellite position (a small holding around a core of broad funds), suited to investors comfortable with deep drawdowns. One trigger to check: if ARKK’s next N-PORT filing still shows Tesla near a tenth of assets, the fund’s fortunes remain tied to one stock.
Contact [email protected] for any questions or corrections.







